

Investing in the Future of Genomic Innovations, Today

BMO MSCI Genomic Innovation Index ETF (ticker: ZGEN)



Why Should I Think About Adding Genomic Innovations to My Portfolio?


Get exposure to a growing megatrend. Genomic Innovators are the leading companies who are investing in future advancements in the genomics space. These companies will be the largest beneficiaries of this megatrend: they will be the owners of the patents for the therapies, treatments and cures that we will rely on in the future.

Growth investing with genomic innovators. We will rely on the technologies and therapies that genomic innovation companies will develop and create, this will lead to exponential growth profiles for these innovative companies in the years to come.

Diversification. Genomic innovation companies are underrepresented in the Canadian marketplace. Therefore, investors may benefit by adding a genomics ETF to a portfolio to not only get exposure to this theme but to also diversify from Canadian equities. ZGEN has a low correlation to the broad Canadian market at 0.67.¹

Genomic Revolution Market Update:

Genomic innovators have been on a run, and this is not a surprise. Over the last three months, the MSCI ACWI IMI Genomic Innovation Index, which represents the global leaders in genomic innovations, returned 21.6% vs the S&P 500 Index return of 13.2%.² Vaccines have been the largest driver of the pandemic recovery and this has put a giant spotlight on mRNA technology which until this year had little funding and hardly any awareness. The leading companies exposed to mRNA technology benefit enormously from the global demand for vaccines. **Moderna** is now a household name, and the company shot up 284% year-to-date (YTD).³ **BioNTech**, who splits its vaccine profits with Pfizer, returned 298% YTD.⁴ Both Moderna and BioNTech are benefitting from continued vaccine demand and the future need for boosters. Going forward mRNA technology will be used to prevent other illnesses, for example, BioNTech is currently developing an mRNA vaccine for malaria. There have also been other recent drivers in genomic innovation companies. Many of these companies are exposed to gene editing and CRISPR cas9 technologies and were beneficiaries of current advancements in this space. For example, **Intellia Therapeutics** made a recent breakthrough during a successful trial where gene-editing technology had its first delivery as medicine into a human body.⁵ This was a crucial step towards developing future cures for genetic diseases.



Source: ¹ Bloomberg September 16, 2021. 3-year correlation of the MSCI ACWI IMI Genomic Innovation Index (CAD) and the S&P/TSX Composite Index (CAD). ² Bloomberg, September 16, 2021. Total return in CAD. You cannot invest directly in an index. ³ Bloomberg, September 3, 2021. ⁴ Bloomberg, September 3, 2021. ⁵ <https://www.nasdaq.com/articles/looking-to-play-intellias-ground-breaking-gene-therapy-2021-07-06>

BMO MSCI Genomic Innovation Index ETF

ZGEN

Distribution Yield: N/A | A

Mgmt. Fee: 0.40%

Risk Rating: Medium

new

Using the BMO MSCI Genomic Innovation Index ETF (ZGEN) to add this megatrend to a portfolio:


The **BMO MSCI Genomic Innovation Index ETF (ZGEN)** is a thematic ETF which strictly focuses on genomic innovation companies and is an efficient way to access a basket of global genomics stocks. ZGEN holds a portfolio of over 200 companies which are global leaders in genomic innovations. **Using an index-based ETF will maximize exposure to the trend of genomic innovations and minimize single stock risk**, which we believe is a powerful way to add this megatrend to a growth portfolio.

A Note About Thematic Investing:

Investing in genomic innovations is **thematic investing**, not sector investing, and it is important for investors to understand the difference. For example, a health care sector ETF includes many other sub industries such as health care services, supplies, equipment and technology. So genomic innovators, many of which are classified within the biotech industry, are not given as heavy a weight in a broader sector portfolio. However, in terms of portfolio construction, investors can use thematic ETFs such as ZGEN in the same way as a sector ETF. It can be added to tilt a portfolio to a targeted exposure, in this case genomic innovations.

Implementation:

To add genomic innovators to your growth portfolio, consider [BMO MSCI Genomic Innovation Index ETF, ZGEN](#).



Source: MSCI, June 30, 2021. The numbers on the bar chart are the number of companies exposed to the respective sub-themes. Please note that a company can be exposed to multiple sub-themes and so the sum of numbers on the chart may not match the total number of holdings in ZGEN.

Top Holdings

| Weight (%) | Name |
|------------|-------------------------------|
| 12.06% | MODERNA INC |
| 5.52% | THERMO FISHER SCIENTIFIC INC |
| 5.14% | ILLUMINA INC |
| 4.85% | WUXI BIOLOGICS CAYMAN INC |
| 4.72% | ROCHE HOLDING AG |
| 4.23% | BRISTOL-MYERS SQUIBB CO |
| 4.05% | VERTEX PHARMACEUTICALS INC |
| 3.34% | AGILENT TECHNOLOGIES INC |
| 2.92% | REGENERON PHARMACEUTICALS INC |
| 2.84% | BAYER AG |
| 2.37% | ICON PLC |
| 2.12% | TELADOC HEALTH INC |
| 1.99% | BIONTECH SE |
| 1.90% | BIO-TECHNE CORP |
| 1.60% | CATALENT INC |

Want to learn more about investing in Genomics?



[Watch.](#) BMO Market Insights Webinar on Genomic Innovations

[Listen.](#) BMO ETFs Podcast on investing in Genomics with ZGEN

Any statement that necessarily depends on future events may be a forward-looking statement. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Although such statements are based on assumptions that are believed to be reasonable, there can be no assurance that actual results will not differ materially from expectations. Investors are cautioned not to rely unduly on any forward-looking statements. In connection with any forward-looking statements, investors should carefully consider the areas of risk described in the most recent simplified prospectus.

BMO Global Asset Management is a brand name that comprises of BMO Asset Management Inc., BMO Investments Inc., BMO Asset Management Corp. and BMO's specialized investment management firms.

This article is for information purposes. The information contained herein is not, and should not be construed as, investment, tax or legal advice to any party. Investments should be evaluated relative to the individual's investment objectives and professional advice should be obtained with respect to any circumstance.

Commissions, management fees and expenses all may be associated with investments in exchange traded funds. Please read the ETF Facts or prospectus before investing. Exchange traded funds are not guaranteed, their values change frequently, and past performance may not be repeated.

For a summary of the risks of an investment in the BMO ETFs, please see the specific risks set out in the prospectus. BMO ETFs trade like stocks, fluctuate in market value and may trade at a discount to their net asset value, which may increase the risk of loss. Distributions are not guaranteed and are subject to change and/or elimination.

BMO ETFs are managed by BMO Asset Management Inc., which is an investment fund manager and a portfolio manager, and a separate legal entity from Bank of Montreal.

The exchange traded funds or securities referred to herein are not sponsored, endorsed or promoted by MSCI, and MSCI bears no liability with respect to any such exchange traded funds or securities or any index on which such exchange traded funds or securities are based. The prospectus contains a more detailed description of the limited relationship MSCI has with BMO Asset Management Inc. and related exchange traded funds.

S&P® and S&P 500® are registered trademarks of Standard & Poor's Financial Services LLC ("S&P") and "TSX" is a trademark of TSX, Inc. These trademarks have been licensed for use by S&P Dow Jones LLC and sublicensed to BMO Asset Management Inc. in connection with ZCN, ZUH, ZSP and ZSP.U (the "ETF") The index or indices are products of S&P Dow Jones Indices LLC and have been licensed for use by BMO Asset Management Inc. in connection with the ETFs. The ETFs are not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC, S&P, TSX or their respective affiliates, and S&P Dow Jones Indices LLC, S&P, TSX and their respective affiliates make no representation regarding the advisability or investing in such ETFs.

For a summary of the risks of an investment in the BMO ETFs or ETF Series of the BMO Mutual Funds, please see the specific risks set out in the prospectus. BMO ETFs and ETF Series trade like stocks, fluctuate in market value and may trade at a discount to their net asset value, which may increase the risk of loss. BMO ETFs are managed by BMO Asset Management Inc., which is an investment fund manager and a portfolio manager, and a separate legal entity from Bank of Montreal. ETF Series of the BMO Mutual Funds are managed by BMO Investments Inc., which is an investment fund manager and a separate legal entity from Bank of Montreal.

®/™Registered trade-marks/trade-mark of Bank of Montreal, used under licence.